CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Growing number of patients being treated in ICUs, NICUs, and emergency departments
3.5.1.2. Increase in geriatric population and surge in incidence and prevalence of chronic diseases
3.5.1.3. Technological advancement in blood gas and electrolyte analyzers

3.5.2. Restraints

3.5.2.1. Complexity involved in interpretation of data

3.5.3. Opportunities

3.5.3.1. Developing economies offer lucrative growth opportunities

CHAPTER 4 BLOOD GAS AND ELECTROLYTE ANALYZERS MARKET, BY TYPE

4.1. OVERVIEW
4.2. ANALYZERS/INSTRUMENTS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market by product type

4.2.4.1. Blood gas analyzers

4.2.4.1.1 Market size and forecast

4.2.4.2. Electrolyte analyzers

4.2.4.2.1. Market size and forecast

4.2.4.3. Combined analyzers

4.2.4.3.1. Market size and forecast

4.2.5. Market by modality

4.2.5.1. Laboratory

4.2.5.1.1. Market size and forecast

4.2.5.2. Benchtop

4.2.5.2.1. Market size and forecast

4.2.5.3. Portable

4.2.5.3.1. Market size and forecast

4.3. CONSUMABLES

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 BLOOD GAS AND ELECTROLYTE ANALYZERS MARKET, BY PRODUCT/BRAND

5.1. OVERVIEW
5.2. I-STAT

5.2.1. Market size and forecast

5.3. GEM PREMIER

5.3.1. Market size and forecast

5.4. ABL FLEX

5.4.1. Market size and forecast

5.5. COBAS

5.5.1. Market size and forecast

5.6. RAPID SERIES

5.6.1. Market size and forecast

5.7. OTHER

5.7.1. Market size and forecast

CHAPTER 6 BLOOD GAS AND ELECTROLYTE ANALYZERS MARKET, BY END USER

6.1. OVERVIEW
6.2. HOSPITAL

6.2.1. Market size and forecast

6.3. CLINICS

6.3.1. Market size and forecast

6.4. AMBULATORY SURGICAL CENTERS

6.4.1. Market size and forecast

6.5. OTHERS

6.5.1. Market size and forecast

CHAPTER 7 BLOOD GAS AND ELECTROLYTE ANALYZERS MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S.: market size and forecast
7.2.5. Canada: market size and forecast
7.2.6. Mexico: market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany: market size and forecast
7.3.5. France market size and forecast
7.3.6. UK: market size and forecast
7.3.7. Italy: market size and forecast
7.3.8. Spain: market size and forecast
7.3.9. Rest of Europe: market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan: market size and forecast
7.4.5. China market size and forecast
7.4.6. India: market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Latin America: market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa: market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES, INC.

8.1.1. Overview
8.1.2. Operating business segments
8.1.3. Business performance

8.2. ALERE, INC.

8.2.1. Overview
8.2.2. Operating business segments
8.2.3. Business performance
8.2.4. Key strategic moves & developments

8.3. ERBA DIAGNOSTICS MANNHEIM GMBH

8.3.1. Overview
8.3.2. Operating business segments
8.3.3. Business performance
8.3.4. Key strategic moves & developments

8.4. INSTRUMENTATION LABORATORY

8.4.1. Overview
8.4.2. Operating business segments
8.4.3. Business performance
8.4.4. Key strategic moves & developments

8.5. MEDICA CORPORATION

8.5.1. Overview
8.5.2. Operating business segments
8.5.3. Business performance
8.5.4. Key strategic moves & developments

8.6. NOVA BIOMEDICAL

8.6.1. Overview
8.6.2. Operating business segments
8.6.3. Business performance

8.7. OPTI MEDICAL SYSTEMS, INC

8.7.1. Overview
8.7.2. Operating business segments
8.7.3. Business performance

8.8. RADIOMETER MEDICAL APS(A SUBSIDIARY OF DANAHER CORPORATION)

8.8.1. Overview
8.8.2. Operating business segments
8.8.3. Business performance

8.9. ROCHE DIAGNOSTICS LIMITED

8.9.1. Overview
8.9.2. Operating business segments
8.9.3. Business performance
8.9.4. Key strategic moves & developments

8.10. SIEMENS AG

8.10.1. Overview
8.10.2. Operating business segments
8.10.3. Business performance